Clinicians’ Perspectives on Cure in Adult Patients with Acute Lymphoblastic Leukemia with Minimal Residual Disease: A Delphi Study
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1865-8652
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Clinicians’ Perspectives on Cure in Adult Patients with Acute Lymphoblastic Leukemia with Minimal Residual Disease: A Delphi Study ; volume:36 ; number:11 ; day:4 ; month:10 ; year:2019 ; pages:3017-3029 ; date:11.2019
Advances in therapy ; 36, Heft 11 (4.10.2019), 3017-3029, 11.2019
- Urheber
-
Gidman, Wendy
Shah, Shweta
Zhang, Lirong
McKendrick, Jan
Cong, Ze
Cohan, David
Ottmann, Oliver
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s12325-019-01099-x
- URN
-
urn:nbn:de:101:1-2020021622552204531375
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
- 14.08.2025, 11:02 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Gidman, Wendy
- Shah, Shweta
- Zhang, Lirong
- McKendrick, Jan
- Cong, Ze
- Cohan, David
- Ottmann, Oliver
- SpringerLink (Online service)
Ähnliche Objekte (12)
Minimal Residual Disease in Acute Lymphoblastic Leukemia
Measurable residual disease quantification in adult patients with KMT2A-rearranged acute lymphoblastic leukemia
Measurable residual disease analysis in paediatric acute lymphoblastic leukaemia patients with ABL-class fusions
Advanced minimal residual disease monitoring for acute lymphoblastic leukemia with multiplex mediator probe PCR
Are measurable residual disease results after consolidation therapy useful in children with acute lymphoblastic leukemia?
Mean residual life cure models for right‐censored data with and without length‐biased sampling
Testing for minimal residual disease in adults with acute lymphoblastic leukemia in Europe: a clinician survey
Curative outcomes following blinatumomab in adults with minimal residual disease B-cell precursor acute lymphoblastic leukemia
ETV6::RUNX1 Acute Lymphoblastic Leukemia: how much therapy is needed for cure?
Intracranial residual lesions following early intensification in a patient with T-cell acute lymphoblastic leukemia: a case report
Travel with Diabetes: A Comprehensive Review for Clinicians
Modelling reassurances of clinicians with hidden Markov models
Minimal Residual Disease in Acute Lymphoblastic Leukemia
Measurable residual disease quantification in adult patients with KMT2A-rearranged acute lymphoblastic leukemia
Measurable residual disease analysis in paediatric acute lymphoblastic leukaemia patients with ABL-class fusions
Advanced minimal residual disease monitoring for acute lymphoblastic leukemia with multiplex mediator probe PCR
Are measurable residual disease results after consolidation therapy useful in children with acute lymphoblastic leukemia?
Mean residual life cure models for right‐censored data with and without length‐biased sampling
Testing for minimal residual disease in adults with acute lymphoblastic leukemia in Europe: a clinician survey
Curative outcomes following blinatumomab in adults with minimal residual disease B-cell precursor acute lymphoblastic leukemia
ETV6::RUNX1 Acute Lymphoblastic Leukemia: how much therapy is needed for cure?
Intracranial residual lesions following early intensification in a patient with T-cell acute lymphoblastic leukemia: a case report
Travel with Diabetes: A Comprehensive Review for Clinicians
Modelling reassurances of clinicians with hidden Markov models
Minimal Residual Disease in Acute Lymphoblastic Leukemia
Measurable residual disease quantification in adult patients with KMT2A-rearranged acute lymphoblastic leukemia
Measurable residual disease analysis in paediatric acute lymphoblastic leukaemia patients with ABL-class fusions
Advanced minimal residual disease monitoring for acute lymphoblastic leukemia with multiplex mediator probe PCR
Are measurable residual disease results after consolidation therapy useful in children with acute lymphoblastic leukemia?
Mean residual life cure models for right‐censored data with and without length‐biased sampling
Testing for minimal residual disease in adults with acute lymphoblastic leukemia in Europe: a clinician survey
Curative outcomes following blinatumomab in adults with minimal residual disease B-cell precursor acute lymphoblastic leukemia
ETV6::RUNX1 Acute Lymphoblastic Leukemia: how much therapy is needed for cure?
Intracranial residual lesions following early intensification in a patient with T-cell acute lymphoblastic leukemia: a case report
Travel with Diabetes: A Comprehensive Review for Clinicians